Stifel maintains its Buy rating on Novo Nordisk shares, with a price target slightly reduced from 960 to 950 DKK.

The analyst reports that Novo Nordisk's share price was very volatile yesterday, due to mixed quarterly results and a less clear short-term outlook.

' We think that yesterday's events could give investors the impression that the investment case is becoming more complex,' the analyst points out.

Stifel reports that this is the first time in two years that it has not revised its figures upwards after a quarterly report.

"With the relatively binary results of Mim8's AdCom and icodec still to come, we think it wise to recommend some diversification in the European pharmaceutical universe", concludes the broker.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.